MarketScreener Editorial Features ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Equities

Delayed Hong Kong S.E. Other stock markets 11:11:47 2024-05-19 pm EDT			5-day change	1st Jan Change
14.76 ^HKD	+1.79%		+2.51%	-50.90%

May. 17	Immuneonco Biopharmaceuticals Gets Regulatory Go-Ahead for Phase 3 Trial of Myelodysplastic Syndrome Drug in China	MT
May. 17	Immuneonco Biopharmaceuticals Inc. Receives Approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China for A Randomized, Double-Blind, Controlled Phase III Clinical Trial of MM01 (Timdarpacept) in Combination with Azacitidine for the First-Line Treatment of Higher-Risk Myelodysplastic Syndrome (HR MDS)	CI

No results for this search